Bayer HealthCare has signed a master agreement for the conduct of clinical trials with the University of Texas MD Anderson Cancer Center aimed at supporting collaborative clinical programs in oncology.
 
Bayer’s oncology franchise is exploring specific treatment approaches for various tumors, including common types of cancer such as prostate, colorectal, and breast cancer, and more rare forms, like kidney, liver and thyroid cancer. MD Anderson Cancer Center is among the world’s most respected centers focused on cancer patient care, research, education and prevention.
 
The two organizations have formed a joint committee comprising clinicians and scientists from Bayer HealthCare’s sites in Berlin, Germany and Whippany, NJ, and from MD Anderson in Houston, TX, to plan and conduct clinical trials with investigational anti-cancer agents developed by Bayer HealthCare.
 
“Bayer is committed to bringing collaborative leadership to life by fostering partnerships with world renowned research centers such as MD Anderson,” said Kemal Malik, M.D., head of Global Development, Bayer HealthCare. “The partnership will bring together thought-leading scientists who will focus on improving the understanding of the biological mechanism of cancer to help identify patients who are likely to respond to specific treatments.”